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Telmisartan Prevents Weight Gain and Obesity Through
Activation of Peroxisome Proliferator-Activated
Receptor-–Dependent Pathways
Hongbo He, Dachun Yang, Liqun Ma, Zhidan Luo, Shuangtao Ma, Xiaoli Feng, Tingbing Cao,
Zhencheng Yan, Daoyan Liu, Martin Tepel, Zhiming Zhu
Abstract—Telmisartan shows antihypertensive and several pleiotropic effects that interact with metabolic pathways. In the
present study we tested the hypothesis that telmisartan prevents adipogenesis in vitro and weight gain in vivo through
activation of peroxisome proliferator-activated receptor (PPAR)-–dependent pathways in several tissues. In vitro,
telmisartan significantly upregulated PPAR- expression in 3T3-L1 preadipocytes in a time- and dose-dependent
manner. Other than enhancing PPAR- expression by 68.217.3% and PPAR- activity by 102.09.0%, telmisartan
also upregulated PPAR- expression, whereas neither candesartan nor losartan affected PPAR- expression. In vivo,
long-term administration of telmisartan significantly reduced visceral fat and prevented high-fat diet-induced obesity in
wild-type mice and hypertensive rats but not in PPAR- knockout mice. Administration of telmisartan did not influence
food intake in mice. Telmisartan influenced several lipolytic and energy uncoupling related proteins (UCPs) and
enhanced phosphorylated protein kinase A and hormone sensitive lipase but reduced perilipin expression and finally
inhibited adipogenesis in 3T3-L1 preadipocytes. Telmisartan-associated reduction of adipogenesis in preadipocytes was
significantly blocked after PPAR- gene knockout. Chronic telmisartan treatment upregulated the expressions of protein
kinase A, hormone-sensitive lipase, and uncoupling protein 1 but reduced perilipin expression in adipose tissue and
increased uncoupling protein 2 and 3 expression in skeletal muscle in wild-type mice but not in PPAR- knockout mice.
We conclude that telmisartan prevents adipogenesis and weight gain through activation of PPAR-–dependent lipolytic
pathways and energy uncoupling in several tissues. (Hypertension. 2010;55:869-879.)
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Abdominal obesity, which increases cardiometabolicrisks, is often associated with hypertension.1 Reduction
of high blood pressure significantly lowers cardiovascular
mortality.2 Evaluation of antihypertensive drugs for their
beneficial effects on weight gain may improve clinical
management of obese patients with hypertension.
Angiotensin II receptor blockers (ARBs) are commonly
used to lower blood pressure.2 Other than their antihyper-
tensive effects, several clinical trials show that ARB can
prevent the onset of type 2 diabetes mellitus.3,4 Recently,
clinical and experimental studies have shown that ARBs
have effects on weight gain and obesity,5–15 which indicate
that ARB could be beneficial for the management of
obesity related hypertension. Previous studies suggested
that several pleiotropic effects of ARBs include upregula-
tion of uncoupling protein (UCP) 1 and angiotensin II
receptor type 1 expression, activation of peroxisome pro-
liferator activated receptor (PPAR)-, increase of adi-
ponectin, and promotion of caloric expenditure.5,7,10,14 –20
However, the precise mechanisms responsible for the
effect of ARBs on fat metabolism remain unresolved.
Recent studies suggested that activation of PPAR- could
prevent high-fat diet-induced obesity in rodents.21–23 In
addition, obesity is characterized by increased fat storage
and reduced lipolysis in adipose tissue and energy uncou-
pling.24 –27 It is unknown whether ARBs may affect
PPAR-, lipolytic pathways, and energy uncoupling, such
as protein kinase A (PKA); hormone-sensitive lipase
(HSL); perilipin, an essential lipid droplet-associated pro-
tein; and UCPs.5,24 –28 In the present study we tested the
hypothesis that telmisartan may prevent adipogenesis in
vitro and weight gain in vivo through activation of
PPAR-– dependent lipolytic pathways and energy uncou-
pling from rodent models.
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Methods
Animal Care
C57BL/6J wild-type mice and PPAR- knockout mice were pur-
chased from Jackson Laboratory (Bar Harbor, ME). Twelve-week–
old male spontaneously hypertensive rats (SHRs) were obtained
from Charles Rivers Laboratories. Animals were given the normal
chow diet (ND group) or high-fat diet (HD group). The high-fat diet
was obtained from SLAC Laboratory Animal Co, Ltd. Mice and rats
were housed in a pathogen-free animal facility and allowed water
and food ad libitum. Food intake was similar under these conditions.
All of the animals were subject to controlled temperature (221°C)
and lighting (lights on 6:00 AM to 6:00 PM). All of the experimental
procedures were performed in accordance with protocols approved
by the Institutional Animal Care and Research Advisory Committee.
Long-Term Administration of Telmisartan In Vivo
Mice or SHRs were assigned to the different experimental proce-
dures: (1) mice were fed with normal chow (control) and chow
mixed into telmisartan 5 mg/kg daily (telmisartan) for 28 weeks; (2)
mice were fed with normal chow or a high-fat diet for 24 weeks, then
telmisartan (5 mg/kg daily) was given additionally by oral gavage for
4 weeks; and (3) SHRs on a normal chow or high-fat diet were
treated with 5 mg/kg daily telmisartan for 16 weeks. Systolic blood
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Figure 1. Telmisartan activates PPAR- in 3T3–L1 preadipocytes and PC12W cells. A, PPAR- expression in 3T3–L1 preadipocytes was
detected by immunoblotting after treatment without (control [Cont]) or with telmisartan (10 mol/L; Telm), candesartan (10 mol/L; Cand), or
losartan (10 mol/L; Losa) for 24 hours; *P0.05 vs control. B, Dose-dependent effect of telmisartan (f) for 24 hours or control () on
PPAR- in 3T3–L1 preadipocytes; *P0.05; **P0.01 vs control. C, Time-dependent effect of telmisartan (10 mol/L; f) or control () on
PPAR- expression; *P0.05 vs control. D, Transcriptional activity of PPAR- in 3T3–L1 preadipocytes, and PC12W cells were evaluated by
luciferase assay after treatment with different concentrations of telmisartan; *P0.05; **P0.01 vs control. E, PC12W cells from the same
passages were transfected with PPRE-luciferase reporter construct with and without PPAR- expression vectors, followed by stimulation with
telmisartan (10 mol/L), GW0742 (10 mol/L), or losartan (10 mol/L). Luciferase activity was measured after 24 hours. Experiments were
repeated 3 times; *P0.05; **P0.01 vs control. F, Effect of telmisartan (10 mol/L; f) on PPAR- in 3T3–L1 preadipocytes; *P0.05 vs con-
trol. G, PPAR- expression in 3T3–L1 preadipocytes was detected without (control; ) or with telmisartan (10 mol/L; f); or telmisartan in
the presence of the PPAR- inhibitor GW9662 (10 mol/L; f) for 24 hours; **P0.001 vs control.
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pressure of SHRs was measured by tail cuff, and body weight was
quantified weekly. At the end of treatment, the animals were fasted
for 12 hours before being euthanized by decapitation. Adipose
tissues were assayed. Visceral fat weight was determined via
dissection of epididymal, retroperitoneal, and mesenteric fat depots.
Representative cross-sections of adipose tissue were analyzed for
cell size according to standard techniques, and the rest was frozen
and stored at 70°C until further processing.
Biochemical Parameters, Histological Analysis,
and Immunohistochemistry
For details, refer to the online Data Supplement, available at
http://hyper.ahajournals.org. The immunohistochemical procedure
was described in our previous study.29
Immunoblotting
Immunoblots of PPAR-, PKA, phosphorylated PKA (p-PKA),
HSL, perilipin, UCP-1, UCP-2, UCP-3, palmitoyltransferase-1
(CPT1), cytochrome c oxidase (COX2), and -actin in tissue were
performed using standard techniques. For details, refer to the online
Data Supplement.
Preadipocyte Culture and Adipocyte
Differentiation Assay
The procedures of preadipocyte culture and adipocyte differentiation
assay were described in our previous studies.21,30 For details, refer to
the online Data Supplement. Other experiments were performed in
isolated preadipocyte cells from visceral adipose tissue of C57BL/6J
or PPAR- knockout mice in the presence of the 10 mol/L of
telmisartan, 10 mol/L of candesartan, 10 mol/L of losartan, and
10 mol/L of GW0742.
Overexpression of PPAR- in
3T3-L1 Preadipocytes
The recombinant adenoviral vectors containing rat PPAR- were
generated as described.21 For details, refer to the online Data
Supplement.
Transfection and Luciferase Assay
PPAR- activity was determined by transactivation assays in 3T3-L1
preadipocytes and angiotensin II receptor type 1 knockout PC12W
cells (Cell Bank, Chinese Academy of Sciences). Cells were plated
in 48-well dishes and transfected by use of the Lipofectamine LTX
Reagent (Invitrogen), delivering 150 ng of the full-length coding
region of rat PPAR- expression plasmid pAdTrack-
cytomegalovirus-PPAR-, 300 ng of luciferase reporter plasmid
tk-peroxisome proliferator response element (PPRE) 3-luc, and
150 ng of pRL-TK renilla luciferase reporter vector as an internal
control. After 6 hours, transfection medium was replaced by 10%
FBS/DMEM and cells were treated with varying concentrations of
the telmisartan and PPAR- agonist GW 0742 and incubated for an
additional 24 hours. Cells were assayed for luciferase and renilla
activity using the Dual-Glo Luciferase Assay System (Promega) and
the Varioskan Flash Type 3001(Thermo Electron Corporation). All
of the treatments were performed in triplicate and normalized for
renilla activity.
Statistics
Data are expressed as meanSEM. Statistical significance of differ-
ences between mean values was assessed by the Student t test or
1-way ANOVA with a Bonferroni multiple comparison post hoc test,
as appropriate. Two-sided P values 0.05 were considered to
indicate statistical significance.
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Figure 2. Effect of PPAR- overexpression or PPAR- activation on adipogenesis in adipocytes. A, Lipid droplets were visualized by oil red O
staining after differentiation of 3T3–L1 preadipocytes with or without PPAR- overexpression; magnification, 200; representative pictures
from 3 to 6 separate experiments are shown. B, PPAR- overexpression was validated by immunoblotting. C, Lipid droplets were analyzed in
primary cultured visceral adipocytes from wild-type mice (WT; top), from PPAR- knockout mice (PPAR-/; middle) or PPAR- null preadi-
pocytes with the adenoviral PPAR- vector (PPAR / rescue; bottom) under control conditions, in the presence of GW0742 or in the pres-
ence of telmisartan. 3T3–L1 preadipocytes were stimulated using 3-isobutyl-1-methylxanthine (0.5 mmol/L), dexamethasone (1.0 mol/L), and
insulin (5.0 g/mL). Magnification, 400; representative photomicrographs of three separate experiments are shown. D and E, Intracellular
TG levels in primary cultured adipocyte from wild-type mice (D) and PPAR- knockout mice (E) with or without GW0742 (10 mol/L) or telm-
isartan (10 mol/L) treatment for 24 hours. Values are meanSEM; n6 per group; **P0.01 vs control.
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Results
Telmisartan Activates PPAR- in
3T3-L1 Preadipocytes
First, we examined whether telmisartan affects PPAR-
protein expression. Compared with control, administration of
telmisartan (10 mol/L), but neither candesartan (10 mol/L)
nor losartan (10 mol/L), significantly increased PPAR-
expression in 3T3-L1 preadipocytes. Telmisartan signifi-
cantly upregulated PPAR- expression by 68.217.3%
(P0.05; Figure 1A).
Figure 1B shows the dose-dependent effect of telmisartan on
PPAR- in 3T3-L1 preadipocytes. We observed that telmisartan
concentrations 1 mol/L significantly increased the PPAR-
expression in these cells. As indicated in Figure 1C, the effect of
A
B 
 
 
 
 
 
 
 
 
 
C              
D 
0 4 8 12 16 20 24 28
10
15
20
25
30
35
40
Control
Telmisartan
PPARδ-/-
Time (weeks)
B
od
y 
w
ei
gh
t (
g)
Control Telmisartan
Vi
sc
er
al
 W
AT
 
Su
b-
W
AT
 
0 4 8 12 16 20 24 28
10
15
20
25
30
35
40
Control
Telmisartan
* **
WT
Time (weeks)
B
od
y 
w
ei
gh
t (
g)
Visceral WAT            Sub-WAT
0.0
2.5
5.0
7.5
10.0
12.5
Control
Telmisartan
*
**
WT
%
 o
f b
od
y 
w
ei
gh
t
Visceral WAT Sub-WAT
0
500
1000
1500
2000
Control
Telmisartan
*
*
WT
A
di
po
cy
te
s 
si
ze（
μm
2 )
Visceral WAT             Sub-WAT
0
500
1000
1500
2000
PPAR δ -/-
Control
Telmisartan
A
di
po
cy
te
s 
si
ze
 ( μ
m
2 )
Su
b-
W
AT
 
Control Telmisartan E 
Visceral WAT Sub-WAT
0.0
2.5
5.0
7.5 Control
Telmisartan
PPARδ-/-
%
 o
f b
od
y 
w
ei
gh
t
F
Vi
sc
er
al
 W
AT
 
Figure 3. Telmisartan affects the rise of body weight in wild-type mice but not in PPAR- knockout mice. Mice were fed with normal
chow (control) and chow plus telmisartan 5 mg/kg daily (telmisartan) for 28 weeks. Effect of telmisartan on rise of body weight (A),
weight of adipose tissue (B), and adipocytes size (C) are depicted in wild-type mice. Magnification, 200; *P0.05; **P0.01 vs con-
trol; WAT indicates white adipose tissue; Sub, subcutaneous fat. Lack of effect of telmisartan on rise of body weight (D), adipocyte size
(E), and adipose tissue weight (F) are depicted in PPAR- knockout mice; Magnification, 200.
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telmisartan on PPAR- expression was time dependent. Admin-
istration of telmisartan for 24 hours significantly increased
PPAR- in 3T3-L1 preadipocytes. Then, we asked whether the
telmisartan-induced upregulation of PPAR- protein expression
is associated with increased PPAR- activity. Treatment of
PPRE-transfected 3T3-L1 cells and PC12W cells with telmisar-
tan dose-dependently induced transcriptional activity of PPAR-
(Figure 1D). Compared with control, telmisartan (10 mol/L)
and PPAR- agonist GW0742 (10 mol/L) significantly in-
creased PPAR- activity (2.420.10-fold and 5.131.25-fold,
respectively, P0.01 versus vehicle-treated cells) in PC12W
cells, but losartan did not (Figure 1E). Telmisartan also increased
PPAR- protein expression in preadipocytes by 347% of the
control (Figure 1F). On the other hand, an increased PPAR-
could also be observed after administration of telmisartan in the
presence of the PPAR- inhibitor GW 9662 (Figure 1G).
PPAR- Overexpression or Activation
Reduces Adipogenesis
Next, we determined whether PPAR- overexpression or
activation might play a role in adipogenesis. We examined
the effect of overexpression or activation of PPAR- on the
adipogenesis in vitro. Oil red O staining for detection of
adipocyte differentiation was investigated. PPAR- overex-
pression reduced lipid droplets in the cytoplasm from cul-
tured 3T3-L1 preadipocytes (Figure 2A). PPAR- overex-
pression was validated by immunoblotting, as shown in
Figure 2B. Administration of GW0742 and telmisartan mark-
edly attenuated adipogenesis (Figure 2C, top) and intracellu-
lar triglyceride (TG) levels (GW0742 0.740.02 mmol/L and
telmisartan 0.690.02 mmol/L versus control
0.890.03 mmol/L; n6 for each group; P0.01) in primary
cultured visceral preadipocytes from wild-type mice (Figure
2D), whereas GW0742 and telmisartan failed to influence
adipogenesis (Figure 2C, middle) and intracellular TG levels
(Figure 2E) in cultured visceral preadipocytes from PPAR-
knockout mice (GW0742 0.900.01 mmol/L and telmisartan
0.960.04 mmol/L versus control 0.890.07 mmol/L; n6
for each group; P0.05). As shown in Figure 2C (bottom),
after transfecting PPAR- null preadipocytes with the recom-
binant adenoviral PPAR- vector, the inhibitory effects of
telmisartan and GW0742 on adipogenesis were rescued
compared with control conditions, supporting the importance
of PPAR- for telmisartan-dependent effects.
Telmisartan Prevents Weight Gain in Mice
Through Activation of PPAR-
We further studied whether telmisartan affects body weight and
adipose tissue in vivo through PPAR-. PPAR- gene knockout
mice and wild-type mice on a normal chow diet were adminis-
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Figure 4. Effect of telmisartan on body weight and PPAR- expression in adipose tissue from wild-type mice. A, Mice were fed with a
normal diet or a high-fat diet for 24 weeks, then telmisartan (5 mg/kg daily) was given additionally by oral gavage for 4 weeks; #P0.05
vs high fat diet (HD); ND  Tel, ND plus telmisartan; HD  Tel, HD plus telmisartan. PPAR- protein expression in visceral (B) and sub-
cutaneous adipose tissue (C) and in skeletal muscle from mice (D) were detected by immunoblotting; *P0.05 vs ND; #P0.05 vs HD.
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trated with telmisartan (5 mg/kg per day) for 28 weeks. Baseline
characteristics of wild-type and PPAR- knockout mice were
included in the online Supplemental Data (Table S1).
Telmisartan significantly reduced body weight, weight
of adipose tissue, and adipocyte size in wild-type mice
(Figure 3A through 3C). Telmisartan significantly reduced
visceral fat from 3.00.4 to 1.20.2 g (P0.01; Figure
3B). In contrast, administration of telmisartan for 28 weeks
did not influence body weight, adipose tissue weight, and
adipocyte size in PPAR- gene knockout mice (Figure 3D
through 3F). Ectopic fat deposition could be observed in
liver from wild-type mice on a high-fat diet (Figure S1).
Plasma TG levels and free fatty acid (FFA) levels were
significantly lower in wild-type mice treated with telmis-
artan than in untreated mice (TG: 1.070.09 mmol/L
versus 1.690.16 mmol/L, P0.01; FFA: 0.550.06 mmol/L
versus 0.790.09 mmol/L, P0.05; n8 to 10). In contrast,
plasma TG and FFA levels were not significantly different in
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Figure 5. Effect of telmisartan on adipose tissue and PPAR- expression in SHRs. SHRs were fed with ND, HD, ND plus telmisartan (5
mg/kg per day; ND  Tel), and HD plus telmisartan (5 mg/kg per day; HD  Tel) for 16 weeks. Body weight (A), percentage of adipose
tissue vs body weight (B), and vs adipocytes size (C) are shown in these groups; magnification, 200; *P0.05; **P0.01 vs ND;
#P0.05; ##P0.01 vs HD. PPAR- protein expression in visceral fat (D) and subcutaneous fat (E) were detected by immunoblotting;
*P0.05; **P0.01 vs ND; #P0.05 vs HD.
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PPAR- gene knockout mice treated with telmisartan and
untreated knockout mice (TG: 1.580.19 mmol/L versus
1.660.18 mmol/L, P0.05; FFA: 0.780.23 mmol/L ver-
sus 0.630.12 mmol/L, P0.05; n5). These findings sug-
gest that long-term administration of telmisartan prevents
weight gain and reduces the size of adipocytes and weight of
adipose tissue by affecting PPAR- in mice.
Telmisartan Prevents High-Fat Diet-Induced
Obesity Through PPAR-
As shown in Figure 4A, body weight was significantly higher
in wild-type mice on a high-fat diet compared with mice on
a normal chow diet. Then telmisartan was added after 24
weeks of a high-fat diet. In these mice, additional adminis-
tration of telmisartan (5 mg/kg daily) for 1 month signifi-
cantly reduced body weight in mice despite a continuous
high-fat diet but had little effect on body weight in mice on a
normal chow diet (Figure 4A). PPAR- expression was
significantly higher in visceral and subcutaneous fat in
wild-type mice treated with telmisartan compared with con-
trol mice (Figure 4B and 4C). Furthermore, a similar effect of
telmisartan on PPAR- expression was also observed in
skeletal muscle (Figure 4D). These findings support the idea
that telmisartan affects PPAR- in several tissues.
Telmisartan Prevents High-Fat Diet-Induced
Obesity in SHRs
Obesity is often associated with hypertension. We further asked
whether the effect of telmisartan on obesity and PPAR- can
also be observed in obese SHRs. SHRs on a normal chow diet
and on a high-fat diet were treated by telmisartan (5 mg/kg per
day) for 16 weeks. Body weight time dependently increased in
SHRs. In contrast, the administration of telmisartan for 16 weeks
significantly reduced the rise of body weight in SHRs on a
normal chow diet, as well as in SHRs on a high-fat diet (Figure
5A; each P0.01 compared with controls). Telmisartan also
significantly lowered systolic blood pressure in SHRs on a
normal chow diet (1078 mm Hg versus 1969 mm Hg;
P0.01) or on a high-fat diet (1136 mm Hg versus
1958 mm Hg; P0.01). High-fat diet significantly increased
weights of subcutaneous and visceral adipose tissue and the size
of adipocytes in obese hypertensive rat. Compared with controls,
the weight of adipose tissue and the size of adipocytes were
significantly lower in SHRs treated with telmisartan (Figure 5B
and 5C). As shown in Figure 5F, PPAR- expressions in visceral
and subcutaneous fat were significantly higher in SHRs treated
with telmisartan compared with controls (Figure 5D and 5E).
Effect of Telmisartan on PPAR-–Dependent
Lipolytic Pathway and Energy Uncoupling
To evaluate whether the effects on telmisartan are mediated
by interaction with lipolytic pathways and energy uncoupling,
we measured the PKA, HSL, and perilipin in both adipose
tissue and preadipocytes. Furthermore, several energy uncou-
pling–related molecules were investigated in skeletal muscle.
First, we showed p-PKA, HSL, and perilipin in adipose tissue
by immunofluorescence (Figure 6A). Second, administration
of the PPAR- agonist, GW0742, or telmisartan significantly
increased the expression of p-PKA and HSL but reduced
perilipin expression in cultured preadipocytes from wild-type
mice. In contrast, GW0742 and telmisartan had no effect on
p-PKA, HSL, and perilipin expression in cultured preadipo-
cytes from PPAR- gene knockout mice (Figure 6B). Third,
we further observed that administration of telmisartan in-
creased the expression of p-PKA and HSL and reduced the
perilipin expression in visceral adipose tissue from wild-type
mice. In contrast, telmisartan did not affect the expression of
p-PKA, HSL, or perilipin in visceral adipose tissue from
PPAR- gene knockout mice (Figure 6C). Fourth, chronic
administration of telmisartan increased the expression of
UCP -1 in brown fat (Figure 6D), UCP-2, and UCP-3 in
skeletal muscle (Figure 6E) but had no effect on CPT1 and
COX2 in skeletal muscle from wild-type mice (Figure 6F).
As expected, telmisartan did not affect the expressions of
energy uncoupling–related molecules mentioned above in
adipose tissue and skeletal muscle from PPAR- gene knock-
out mice (Figure 6D through 6F).
Discussion
The major findings of this study are that telmisartan signifi-
cantly upregulated PPAR- expression and activity in 3T3-L1
preadipocytes, activated PPAR-–dependent lipolytic path-
way, and finally reduced adipogenesis in vitro. The effect of
telmisartan on lipolysis was abolished after PPAR- gene
knockout of preadipocytes. In vivo, long-term administration
of telmisartan significantly reduced the rise of body weight
and prevented high-fat diet-induced obesity in wild-type mice
and hypertensive rats but not in PPAR- knockout mice.
Telmisartan increased the expression of PPAR- and several
lipolytic and energy uncoupling–related proteins, including
PKA, HSL, and UCPs in adipose tissue and skeletal muscle
from wild-type mice and SHRs. This effect of telmisartan
could not be observed in PPAR- knockout mice.
Currently, it is unclear which drugs may be superior to
manage obesity-related hypertension. However, antihyperten-
sive drugs showing antiobese properties may be beneficial for
obese subjects with hypertension. ARBs are generally used to
lower blood pressure.2 Other than their antihypertensive effect,
several ARBs have been shown to prevent the new-onset
diabetes mellitus, which is supposed be related to PPAR-.17,18
Furthermore, Shimabukuro et al11 showed that the visceral fat
area, determined by abdominal computed tomography scan, was
Figure 6. Effect of telmisartan on lipolysis and energy uncoupling. A, Representative immunofluorescence images showing colocaliza-
tion of HSL, p-PKA, and perilipin in visceral adipose tissue. Bottom panel of each group shows the negative control performed by omit-
ting the primary antibody. Magnification, 200. B, Protein expression of PKA, p-PKA, HSL, and perilipin in the primary cultured visceral
adipocytes obtained from wild-type mice and PPAR- knockout mice in the absence (control) or in the presence of telmisartan
(10 mol/L) or PPAR- agonist GW0742 (10 mol/L) for 24 hours; *P0.05; **P0.01 vs control. C, Protein expressions of PKA, p-PKA,
HSL, and perilipin in visceral fat from wild-type mice and PPAR- knockout mice treated with or without telmisartan (5 mg/kg per day);
*P0.05; **P0.01 vs control. Wild-type mice and PPAR- knockout mice were fed with ND and ND plus telmisartan (5 mg/kg per day;
ND  Tel) for 28 weeks. D, UCP-1 protein expression in brown fat. E, UCP-2 and UCP-3 protein expressions in skeletal muscle. F,
CPT1 and COX2 protein expressions in skeletal muscle. *P0.05; **P0.01 vs normal chow.
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reduced in hypertensive patients treated with telmisartan for 24
weeks, whereas treatment of patients with amlodipine did not
affect abdominal fat. Chujo et al31 reported that telmisartan
treatment decreases visceral fat accumulation and improves
serum levels of adiponectin and vascular inflammation markers
in Japanese hypertensive patients.
In addition, a recent clinical trial showed that administra-
tion of irbesartan significantly reduced waist circumference
in hypertensive patients with metabolic syndrome.9 Several
experimental studies further demonstrated that mice and rats
treated with different ARBs show reduced weight gain.11–14
Although telmisartan was reported to reduce the visceral fat,
it did not influence body weight or body mass index either in
the Ongoing Telmisartan Alone and in Combination With
Ramipril Global Endpoint Trial or in the Prevention Regimen
for Effectively Avoiding Second Strokes study.32,33 A recent
study suggested that body mass index and waist circumfer-
ence do not adequately mirror visceral fat accumulations in
different racial/ethnic groups.34
The effects of ARB on fat metabolism may be mediated by
several pathways, including upregulation of UCP1 and an-
giotensin II type 2 receptor expression,5,15 activation of
PPAR-,13,16–18 increase of adiponectin,13 and promotion of
caloric expenditure.5,14 However, the underlying mechanisms
are a matter of debate. For example, telmisartan is regarded as
a partial agonist for PPAR-16–18; however, PPAR- agonists
such as rosiglitazone promote adipocyte differentiation and
lead to weight gain.13,35 Furthermore, Clemenz et al36 recently
identified the telmisartan as a partial PPAR- agonist at least
in the liver. In addition, Benson et al18 showed that telmisar-
tan can also inhibit the proliferation of cells that lack
angiotensin II receptors and cells treated with a PPAR-
antagonist, suggesting that the antiproliferative effects of
telmisartan may involve more than just angiotensin II recep-
tor blockade or activation of PPAR-. Therefore, published
data and our present findings indicate that the actions of
telmisartan were not restricted to PPAR- alone, but telmis-
artan may affect different PPAR subtypes.
Now, the present study including PPAR- knockout in vitro
and in vivo clearly demonstrates that the effects of telmisartan
are mediated by its effect on PPAR-. The present findings
support results by Wang et al20 showing that activation or
overexpression of PPAR- can prevent high-fat–induced obesity
and weight gain by promoting FFA oxidation in adipose tissue.
First, we demonstrated that telmisartan significantly upregu-
lated PPAR- expression and activity in 3T3-L1 preadipocytes.
Second, administration of telmisartan, the PPAR- agonist,
GW0742, or PPAR- overexpression reduced accumulation of
lipid droplets in cultured preadipocytes. Third, long-term admin-
istration of telmisartan increased PPAR- expression and re-
duced weight gain and high-fat–induced obesity in wild-type
mice. Fourth, the inhibitory effect of telmisartan on weight gain
could not be observed in PPAR- knockout mice. Telmisartan
may affect PPAR- because of its high lipophilicity, which is
required to obtain sufficient high penetration rates to bind to
intracellular PPAR-.17,18 The region where telmisartan may
bind to that transcription factor is unknown yet.
Obesity is characterized by increased fat storage in the
form of TGs in adipose tissue. In addition, lipolysis has been
found to be impaired in obesity.37 In humans, catecholamines
and insulin are the most important hormones regulating
adipocyte lipolysis. HSL is the predominant lipase effector of
catecholamine-stimulated lipolysis in adipocytes.27 HSL-
dependent lipolysis in response to catecholamines is mediated
by PKA-dependent phosphorylation of perilipin, an essential
lipid droplet–associated protein.25 It is believed that phos-
phorylation of perilipin is important for the translocation of
HSL from the cytosol to the lipid droplet, a key event to
stimulate lipolysis.24–27
In the present study, we show that either activation of
PPAR- by GW0742 or by telmisartan significantly increased
p-PKA and HSL but reduced perilipin expression in preadi-
pocytes. Furthermore, in wild-type mice, long-term adminis-
tration of telmisartan increased the expression of PPAR-,
p-PKA, and HSL but reduced the expression of perilipin in
visceral fat. By contrast, the effects of telmisartan on p-PKA
and HSL were abolished in PPAR- knockout mice. These
results indicate that activation of PPAR- stimulates the
lipolytic pathway. Given the wide expression of PPAR-, we
showed that the observed effects of telmisartan in adipose
tissue could also be obtained in skeletal muscle. Our addi-
tional experiments showed that telmisartan upregulated
UCP-1 expression in brown fat and expressions of UCP-2 and
UCP-3 but had no effect on expressions of CPT1 and COX2
in skeletal muscle. These data supported the notion that the
effect of telmisartan is not restricted to fat tissue but a
common cellular pathway. In addition, telmisartan can
improve insulin sensitivity, supporting the hypothesis that
telmisartan may exert additional benefit in the manage-
ment of obese patients with hypertension.38,39 The benefi-
cial effects of telmisartan may be caused by its lipolysis
and energy uncoupling, which is in agreement with recent
studies.40,41 Benson et al18 and Schupp et al19 have shown
that telmisartan dose-dependently induced fatty acid bind-
ing protein 2 expression that is an adipogenic marker
through PPAR- activation. However, Janke et al16 re-
ported that 1 mol/L of telmisartan increased lipoprotein
lipase expression that is one of the key genes involved in
TG breakdown, and 10 mol/L of telmisartan slightly
reduced lipid content in preadipocytes through PPAR-
activation. In the present study, we showed that 10 mol/L
of telmisartan significantly promoted lipolytic pathway
and increased PPAR- expression and inhibited adipogen-
esis in 3T3-L1 preadipocytes through PPAR- activation. These
somewhat discrepant findings reported in the literature indicate
that several pathways may finally determine the effect of
telmisartan on adipogenesis by interaction with PPAR- and
PPAR-.
Perspectives
The present study gives experimental evidence that telmisartan
prevents lipogenesis and weight gain through activation of
PPAR-–dependent lipolytic pathways in adipose tissue and
energy uncoupling in skeletal muscle. Our data point toward a
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previously unrecognized role of telmisartan in fat metabolism
and energy uncoupling, which may be relevant for the manage-
ment of obese patients with hypertension. Additional benefit in
the treatment of obese patients with hypertension using ARBs
including telmisartan would be greatly appreciated and should
be investigated in future clinical trials.
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Materials and Methods 
Biochemical parameters 
Blood was obtained from the carotid artery, and then the serum was separated and 
 2
immol/Lediately frozen at -70°C until assayed. Levels of serum glucoses, 
triglycerides, and free fatty acids were measured using commol/Lercially available 
assay kits (Applygen Technologies Inc., China). 
Histological analysis 
Adipose tissue was fixed with 10% formalin and embedded in paraffin. 
Twenty-micron sections were cut and stained with hematoxylin and eosin for 
microscopic examination (Nikon, TE2000). 
Immunohistochemistry 
Fresh adipose tissue was fixed with 10% formalin for 10 minutes at room temperature, 
washed with phosphate buffered saline (PBS) and then permeabilized with PBS 
containing 0.5% Triton X-100 for 20 minutes at room temperature. Sections of 
adipose tissues were incubated with PBS containing with 5% bovine serum and 0.1% 
Triton X-100 for 1 hour at room temperature. Then adipose tissues were incubated 
with rabbit anti-p-PKAThr198, anti-PKA, HSL, perilipin, and PPAR δ antibodies (Santa 
Cruz, USA) over night at 4°C. Adipose tissue sections were washed and incubated 
with antibodies conjugated to a fluorescent probe FITC-conjugated goat anti-rabbit 
IgG (Santa Cruz Biotechnology, USA), 1:200 for 30 minutes at room temperature. In 
the negative control experiments which were performed by omitting the primary 
antibody. After removing the unbound secondary antibodies by washing the 
preparations with PBS, imaging was performed using the fluorescence microscope 
(Nikon, TE2000).1 
Immounoblotting 
Immounoblots of PPAR δ, PKA, p-PKA, HSL, perilipin, UCP 1, 2, 3, 
palmitoyltransferase-1 (CPT1), cytochrome c oxidase (COX2) and β-actin in tissue 
were performed using standard techniques. Primary antibodies (Santa Cruz, CA) were 
used for adipose tissue, skeletal muscle and 3T3-L1-preadipocytes cells. Tissue was 
homogenized in high-salt extraction buffer containing 50 mmol/L Tris, 1 ml NP40, 1 
ml TritionX-100, 0.1 g sodium dodecyl sulfate, 150 mmol/L NaCl, 2 mmol/L 
ethylenediaminetetraacetic acid, 1 mmol/L ethylene 
glycol-bis(2-aminoethylether)-N,N',N'-tetraacetic acid. Tissue was transferred to 
Eppendorf tubes, and homogenized by sonication for 5 seconds. The protein 
supernatant was separated by centrifugation, and protein concentrations were 
determined with Bio-Rad protein assay reagent (Bio-Rad, Hercules CA). Proteins 
were separated by using 10% SDS-polyacrylamide gel, transferred to polyvinylidene 
difluoride membranes at 90 mA overnight, and detected with the ECF kit (Amersham). 
After incubation with the secondary antibodies for 1 hour, the proteins were detected 
by enhanced chemiluminescence and quantified using a 5 Gel Doc 2000 Imager 
(Bio-Rad).  
Preadipocytes culture and adipocytes differentiation assay  
Adipose tissue was processed, including the careful removal of fibrous tissue and 
blood vessels, followed by collagenase digestion. After centrifugation, floating mature 
adipocytes were separated from the stromal-vascular cell pellet, which was subjected 
to additional filtrations (25 mm final pore size) to yield the preadipocytes fraction. 
Primary cultured murine preadipocytes and 3T3-L1 preadipocytes (Cell Bank, 
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Chinese Academy of Sciences, Shanghai, China) were cultured and maintained in 
Dulbecco’s modified Eagle’s medium supplemented with 10% fetal calf serum 
(HyClone) containing 100 µg/ml penicillin and 100 µg/ml streptomycin (Gibco) as 
previously described.1 The adipocytes differentiation assay was performed as 
described.2  Briefly, after reaching confluence 3T3-L1-preadipocytes were treated 
with vector alone for control, adenoviral vector containing rat PPAR δ, Cells were 
fixed and stained with oil red O (Sigma–Aldrich). Red staining shows lipid droplets in 
the cytoplasm indicating adipocytes differentiation. In additional experiments PPAR δ 
expression in 3T3-L1 preadipocytes cells in vitro was determined after stimulation 
with 3-isobutyl-1-methylxanthine (0.5 mmol/L), dexamethasone (1 µmol/L), and 
insulin (5 µg/ml). Other experiments were performed in isolated preadipocytes cells 
from visceral adipose tissue of C57BL/6J or PPAR δ knockout mice in the presence 
of the 10µmol/L telmisartan, 10µmol/L candesartan, 10 µmol/L losartan and 10 
µmol/L GW0742. 
The recombinant adenoviral vectors containing rat PPAR δ were generated as 
described.3 The cDNA encoding rat PPAR δ was amplified by RT-PCR using the 
isolated total RNA as the template from the white fat. Recombined shuttle plasmid p 
Ad Track-CMV-PPAR δ was constructed by linking the pAdTrack-CMV with PPAR 
δ and was sequenced. For generation of recombinant adenoviral plasmids, 
pAdTrack-CMV-PPAR δ was linearized with PmeI, and was transformed into 
electrocompetent Escherichia coli BJ5183 cells, which contained adenoviral backbone 
vectors (pAdEasy-1). Clones that had inserts were screened by restriction 
endonuclease digestions. Once confirmed, supercoiled plasmid DNA was transformed 
into LX10 cells for large-scale amplification. For production of adenoviruses in 
AD293 cells, a transfection mix was prepared by adding 4μg of PacI linearized 
plasmid DNA, purified by gel extraction, and 10μL of Lipofectamine 2000 
(Invitrogen). Transfected cells were monitored for green fluorescent protein 
expression and collected 7–10 days after transfection by scraping cells off flasks and 
pelleting them along with any floating cells in the culture. After three cycles of 
freezing in a methanol dry ice bath and rapid thawing at 37°C, supernatant of viral 
lysate was used to infect AD293 cells in flasks. Three to four days later, viruses were 
harvested as described above. 10 MOI of viruses were infected into 3T3-Li 
preadipocyte. After 3hrs of infection, cells were induced to differentiate.  
 
References 
 
 
1. Liu DY, Maier A, Scholze A, Rauch U, Boltzen U, Zhao ZG, Zhu ZM, Tepel M. 
High glucose enhances transient receptor potential channel canonical type 6 
dependent calcium influx in human platelets via phosphatidylinositol 3-kinase 
dependent pathway. Arterioscler Thromb Vasc Biol. 2008;28:746-751 
2. Zhang LL, Yan Liu D, Ma LQ, Luo ZD, Cao TB, Zhong J, Yan ZC, Wang LJ, 
Zhao ZG, Zhu SJ, Schrader M, Thilo F, Zhu ZM, Tepel M. Activation of transient 
receptor potential vanilloid type-1 channel prevents adipogenesis and obesity. Circ 
 4
Res. 2007; 100:1063-1070. 
3. Yan ZC, Liu DY, Zhang LL, Shen CY, Ma QL, Cao TB, Wang LJ, Nie H, Zidek W, 
Tepel M, Zhu ZM. Exercise reduces adipose tissue via cannabinoid receptor type 
1 which is regulated by peroxisome proliferator-activated receptor-δ. Biochem 
Biophys Res Comm. 2007; 354:427-433. 
 
 
 
 
 
 
 
 
 
Supplemental table and figure 
 
Table S1. Baseline characteristics of wild type and PPAR δ knockout mice 
 
Parameters WT PPAR δ -/- 
HR (beats/min) 549±45.5 533±50.4 
SBP (mmol/LHg) 106.3±3.07 109.0±3.78 
TC   (mmol/L) 2.32±0.11 2.19±0.19 
LDL-c (mmol/L) 0.84±0.07 0.74±0.04 
HDL-c  (mmol/L) 0.71±0.09 0.70±0.05 
Glucose (mmol/L) 6.07±0.41 6.16±0.47 
Insulin  (μIU/ml) 33.17±3.22 37.16±6.87 
Food intake 
(g/animal/day) 
4.33±0.04 4.56±0.06 
 
WT, wild-type mice; PPAR δ -/-, PPAR δ -/- mice; HR, heart rate; SBP, systolic 
blood pressure; TC, total cholesterol; LDL-C, low density lipoprotein-cholesterol; 
HDL-C, high density lipoprotein-cholesterol; Results are means ± SEM for 6-12 
animals.  
 
 
 
 
 
Figure S1 Ectopic fat deposition in liver 
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Figure S1. Histological examination of liver from mice on normal diet (ND) and on 
high fat diet (HD) 
 
 
